addition, CLZ is the only antipsychotic drug currently approved for treatmentresistant schizophrenia. The FDA has recently permitted greater flexibility in deciding whether to continue or rechallenge CLZ in patients. [2] However, CLZ, although a common evidence-based treatment in the field of mental health, is underutilized. The monitoring of CLZ is burdensome and involves frequent invasive blood draws and its treatment efficacy is suboptimal due to the difficulty in titrating its dose, since over dosage results in toxicity as well as possible side effects such as weight gain, blurred vision, confusion, fever, sweating, and dizziness. [3][4][5] Since CLZ is the only antipsychotic with a defined efficacious clinical range, [6,7] analyzing CLZ blood levels in patients easily and accurately provides important information about the clinical range. For example, CLZ serum levels that are higher than 600 ng mL â1 (1.84 ”mol L â1 ) have been associated with severe side effects, toxicity, seizure, and myocarditis. [8][9][10][11][12][13][14] However, psychiatrists estimate that CLZ blood levels should be higher than a 350 ng mL â1 (1.07 ”mol L â1 ) threshold level to achieve effective treatment. [15,16] Therefore, clinicians have been advocating therapeutic drug monitoring (TDM) for CLZ therapy [9,17] that can be rapidly done at the point-of-care (PoC), such as at the physician's office or at home. Along the lines of the medical treatment revolution that the glucose finger-prick blood test provided for diabetes patients, in situ analysis of CLZ blood levels in microliter samples would enable rapid CLZ detection in finger-pricked blood of schizophrenia patients. Such a blood test would provide rapid assessment of CLZ treatment efficacy, which would better manage schizophrenia treatment and care.Current analytical methods for TDM of CLZ blood levels have limited capabilities to rapidly measure CLZ levels in microliter samples. [18][19][20][21][22][23][24][25][26] Liquid chromatography, followed by tandem mass spectrometry (LC-MS/MS), [23] is the gold standard and is available in commercial laboratories. A variation of the method used for venous blood has been adapted to low-volume capillary blood using dried blood spot testing. [24,25] Briefly, the sample is dehydrated on filter paper, transferred to an analytical laboratory, and rehydrated for further analysis using an LC-MS/MS. Although the LC-MS/MS method provides The antipsychotic clozapine is the most effective medication available for schizophrenia and it is the only antipsychotic with a known efficacious clinical range. However, it is dramatically underutilized due to the inability to test clozapine blood levels in finger-pricked patients' samples. This prevents obtaining immediate blood levels information, resulting in suboptimal treatment. The development of an electrochemical microsensor is presented, which enables, for the first time, clozapine detection in microliters volume whole blood. The sensor is based on a microelectrode modified with micrometer-thick biop...